Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown

Executive Summary

Where can HHS go it alone, and where does it need Congress?

Related Content

Will CBO Score CREATE Momentum For Generic Bill's Passage?
Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple
Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing
Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA's Abram Makes The Case For 180-Day Exclusivity Reform





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts